Steven Chmura to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Steven Chmura has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.789
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.513
-
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
Score: 0.502
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.427
-
Reply to S.C. Formenti et al. J Clin Oncol. 2018 09 01; 36(25):2662-2663.
Score: 0.109
-
Treatment of brain metastases. Oncology. 2014; 87(6):321-9.
Score: 0.084
-
An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014 Apr; 117(2):321-7.
Score: 0.081
-
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
Score: 0.038
-
Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol. 2022 Jan-Feb; 12(1):68-77.
Score: 0.034